This report was first published by Endpoints News. To see the original version, click here
Eli Lilly is going big on in vivo CAR-T therapy.
The company said Monday that it would buy Kelonia Therapeutics, which has a Phase 1 program for multiple myeloma and a couple of preclinical candidates, in a deal worth up to $7 billion that includes $3.25 billion upfront.
您已阅读8%（360字），剩余92%（4303字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。